Platform Overview

EVIIVE is the next generation biomarker discovery platform delivering precise diagnostics in majority of immuno-oncology (IO) diseases by breaking personalized medicine barriers.

Green microscopic organism with textured surface and smaller structures surrounding it on a black background.

Unlike static biomarkers, EVs reveal dynamic immune-tumor and immune-metabolic interactions — enabling more precise treatment selection, response prediction, and longitudinal monitoring. Our proprietary antibody panels and analytical engine deliver clinically meaningful insights from just a small volume of plasma.

IMPASS/IMPACT

Single EV discovery technology developing precision diagnostics for cancers with real & high unmet needs.

IMPASS

IMmune PAthogenesis Surveillance System for immune profiling and subpopulation stratification

Our platform begins with high-dimensional immune profiling from blood, using flow cytometry and machine learning to resolve immune cell-derived EV subpopulations. This step identifies distinct patient subgroups based on immune activity, treatment responsiveness, and biomarker expression. The resulting IMPASS profiles can already function as a standalone diagnostic readout—offering stratification power for clinical trials and treatment decisions.

IMPASS

IMmune PAthogenesis Surveillance System for immune profiling and subpopulation stratification

IMPASS

IMmune PAthogenesis Surveillance System for immune profiling and subpopulation stratification

IMPACT

IMmune PAthogenesis Curated Target for mechanistic insights and therapeutic discovery

Building on the subpopulations identified in IMPASS, the IMPACT module applies multi-omics (RNA, DNA, proteomics) to reveal the molecular signatures driving immune phenotypes. These insights go beyond diagnostics—unlocking new therapeutic targets, resistance pathways, and patient-specific mechanisms that inform drug development and personalized immunotherapy design.

IMPACT

IMmune PAthogenesis Curated Target for mechanistic insights and therapeutic discovery

IMPACT

IMmune PAthogenesis Curated Target for mechanistic insights and therapeutic discovery

Our Performance

Value creation by personalized diagnostics: IODx ensures every patient receive the right treatment to maximize chances of complete cure.

97%

*

Accuracy in predicting IO response

80%

*

Cure success rate

* Initial pilot study data and projected estimation.

A woman with red hair and a black sleeveless top smiling confidently in a bright, modern indoor setting.

“Most current biomarkers rely on indirect signals. We’re working with something more immediate—extracellular vesicles—as a way to observe biology closer to how it actually behaves.”

Publications

Modelling liver cancer microenvironment using a novel 3D culture system

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer

Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures

Modular cytosine base editing promotes epigenomic and genomic modifications

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Serum extracellular vesicles profiling is associated with COVID-19 progression and immune responses

Assessing Extracellular Vesicles in Human Biofluids Using Flow-Based Analyzers

Intercellular Epigenomic Signalling via Extracellular Vesicles During B Cell Maturation